Nanobac Pharmaceuticals, Inc.: New Evidence on Calcifying Nanoparticle as a Cause of Chronic Infection, and Potential Danger of Other Nano-Apatite Particles Used in Medicine

TAMPA, Fla.--(BUSINESS WIRE)--Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) (“Nanobac” or “the Company”) announces the publication of correspondence in the June 23, 2007 issue of The Lancet that demonstrates new evidence that further defines the infectious role of Calcifying Nanoparticles (CNPs).